Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.

Gelijkaardige items

• Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
  door: Powe, N, et al.
  Gepubliceerd in: (1993)
• Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients.
  door: Powe, N, et al.
  Gepubliceerd in: (1994)
• A review of the first year of Medicare coverage of erythropoietin.
  door: Griffiths, R, et al.
  Gepubliceerd in: (1994)
• Early dosing practices and effectiveness of recombinant human erythropoietin.
  door: Powe, N, et al.
  Gepubliceerd in: (1993)
• The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients.
  door: de Lissovoy, G, et al.
  Gepubliceerd in: (1994)